AU2015301484B2 - Polymorphs of selinexor - Google Patents

Polymorphs of selinexor Download PDF

Info

Publication number
AU2015301484B2
AU2015301484B2 AU2015301484A AU2015301484A AU2015301484B2 AU 2015301484 B2 AU2015301484 B2 AU 2015301484B2 AU 2015301484 A AU2015301484 A AU 2015301484A AU 2015301484 A AU2015301484 A AU 2015301484A AU 2015301484 B2 AU2015301484 B2 AU 2015301484B2
Authority
AU
Australia
Prior art keywords
crystalline form
structural formula
compound
single crystalline
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015301484A
Other languages
English (en)
Other versions
AU2015301484A1 (en
Inventor
Brian Clinton AUSTAD
David G. Roe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karyopharm Therapeutics Inc
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of AU2015301484A1 publication Critical patent/AU2015301484A1/en
Application granted granted Critical
Publication of AU2015301484B2 publication Critical patent/AU2015301484B2/en
Priority to AU2020203246A priority Critical patent/AU2020203246B2/en
Priority to AU2021286266A priority patent/AU2021286266B2/en
Priority to AU2024202835A priority patent/AU2024202835B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2015301484A 2014-08-15 2015-08-14 Polymorphs of selinexor Active AU2015301484B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020203246A AU2020203246B2 (en) 2014-08-15 2020-05-19 Polymorphs of selinexor
AU2021286266A AU2021286266B2 (en) 2014-08-15 2021-12-14 Polymorphs of selinexor
AU2024202835A AU2024202835B2 (en) 2014-08-15 2024-04-30 Polymorphs of selinexor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462038069P 2014-08-15 2014-08-15
US62/038,069 2014-08-15
PCT/US2015/045395 WO2016025904A1 (en) 2014-08-15 2015-08-14 Polymorphs of selinexor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203246A Division AU2020203246B2 (en) 2014-08-15 2020-05-19 Polymorphs of selinexor

Publications (2)

Publication Number Publication Date
AU2015301484A1 AU2015301484A1 (en) 2017-03-02
AU2015301484B2 true AU2015301484B2 (en) 2020-02-20

Family

ID=53969460

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2015301484A Active AU2015301484B2 (en) 2014-08-15 2015-08-14 Polymorphs of selinexor
AU2020203246A Active AU2020203246B2 (en) 2014-08-15 2020-05-19 Polymorphs of selinexor
AU2021286266A Active AU2021286266B2 (en) 2014-08-15 2021-12-14 Polymorphs of selinexor
AU2024202835A Active AU2024202835B2 (en) 2014-08-15 2024-04-30 Polymorphs of selinexor

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020203246A Active AU2020203246B2 (en) 2014-08-15 2020-05-19 Polymorphs of selinexor
AU2021286266A Active AU2021286266B2 (en) 2014-08-15 2021-12-14 Polymorphs of selinexor
AU2024202835A Active AU2024202835B2 (en) 2014-08-15 2024-04-30 Polymorphs of selinexor

Country Status (18)

Country Link
US (7) US10519139B2 (enExample)
EP (2) EP4112615A1 (enExample)
JP (3) JP6777626B2 (enExample)
KR (1) KR102608259B1 (enExample)
CN (3) CN111481553B (enExample)
AU (4) AU2015301484B2 (enExample)
CA (1) CA2957266A1 (enExample)
CO (1) CO2017001884A2 (enExample)
DK (1) DK3180331T3 (enExample)
EA (1) EA201790384A1 (enExample)
ES (1) ES2926377T3 (enExample)
IL (1) IL250328B (enExample)
MA (1) MA40254B1 (enExample)
MX (2) MX388170B (enExample)
SG (2) SG11201700789SA (enExample)
UA (1) UA123535C2 (enExample)
WO (1) WO2016025904A1 (enExample)
ZA (1) ZA201700880B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087342A1 (es) 2011-07-29 2014-03-19 Karyopharm Therapeutics Inc Moduladores del transporte nuclear que contienen hidrazida y sus usos
SMT202000347T1 (it) 2012-05-09 2020-07-08 Biogen Ma Inc Modulatori di trasporto nucleare e loro usi
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
KR102322794B1 (ko) 2013-06-21 2021-11-05 카리오팜 쎄라퓨틱스, 인코포레이티드 핵수송 조절인자 및 이의 용도
SG11201700789SA (en) * 2014-08-15 2017-02-27 Karyopharm Therapeutics Inc Polymorphs of selinexor
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
EP3565813A1 (en) 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2019232724A1 (en) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020072008A1 (en) * 2018-10-04 2020-04-09 Deva Holding Anonim Sirketi Novel solid dispersions of selinexor
BR112021016762A2 (pt) * 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor
EP3962898A1 (en) 2019-05-01 2022-03-09 Karyopharm Therapeutics, Inc. Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors
US20220218725A1 (en) * 2019-05-16 2022-07-14 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
WO2022087218A1 (en) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Crystalline form of selinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
AU2022276509A1 (en) 2021-05-20 2023-12-07 Karyopharm Therapeutics Inc. Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
WO2023122014A1 (en) * 2021-12-20 2023-06-29 Raytheon Technologies Corporation Particle enhancement of ceramic matrix composites, method of manufacture thereof and articles comprising the same
CN116675677B (zh) * 2023-08-02 2023-09-26 中国林业科学研究院林产化学工业研究所 一种c8漆酚衍生物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019548A1 (en) * 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Hydrazide containing nuclear transport modulators and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
EP0793653A1 (en) 1994-11-23 1997-09-10 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
EP1544197A1 (en) 1996-04-04 2005-06-22 Shionogi & Co., Ltd. Intermediates for cephem compounds
DE69723267T2 (de) 1996-04-25 2004-04-22 Nissan Chemical Industries, Ltd. Ethylenderivate und pestizide
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
US6743585B2 (en) 1999-09-16 2004-06-01 Agilent Technologies, Inc. Methods for preparing conjugates
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
CA2465978C (en) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
EP2261218B1 (en) 2004-05-26 2013-04-03 Eisai R&D Management Co., Ltd. Imidazole compound for use as an intermediate in the production of cinnamide compounds
MX2007001634A (es) 2004-08-11 2007-04-23 Kyorin Seiyaku Kk Nuevo derivado de acido amino benzoico ciclico.
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
TWI330639B (en) * 2005-11-15 2010-09-21 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
GEP20115139B (en) 2006-03-09 2011-01-10 Eisai R&D Man Co Ltd Polycyclic cinnamide derivative
CA2648804C (en) 2006-04-07 2014-05-27 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
EP2014652B1 (en) 2006-04-18 2014-08-06 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor
KR101130380B1 (ko) 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
CA2658925C (en) 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
CA2662112A1 (en) 2006-09-05 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Imidazole derivatives and their use as cannabinoid type 2 (cb2) receptor modulators
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
JP2010519337A (ja) 2007-02-26 2010-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド カルバメート化合物
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2011006100A1 (en) 2009-07-09 2011-01-13 Crescendo Therapeutics, Llc Method of wound healing and scar modulation
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
WO2011109799A1 (en) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
WO2012099807A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
EA201490406A1 (ru) 2011-07-29 2014-07-30 Кариофарм Терапевтикс, Инк. Модуляторы ядерного транспорта и их применение
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
SMT202000347T1 (it) 2012-05-09 2020-07-08 Biogen Ma Inc Modulatori di trasporto nucleare e loro usi
US10202366B2 (en) * 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
KR102322794B1 (ko) 2013-06-21 2021-11-05 카리오팜 쎄라퓨틱스, 인코포레이티드 핵수송 조절인자 및 이의 용도
US11567063B2 (en) * 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
US10969391B2 (en) 2014-07-11 2021-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers
WO2016015597A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
SG11201700789SA (en) 2014-08-15 2017-02-27 Karyopharm Therapeutics Inc Polymorphs of selinexor
WO2017040311A1 (en) 2015-08-28 2017-03-09 The Trustees Of Columbia University In The City Of New York Systems and methods for matching oncology signatures
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) * 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
EP3565813A1 (en) * 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN106831731B (zh) 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
CA3131720A1 (en) 2019-03-27 2020-10-01 Andrea Califano Biomarkers for selinexor
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
ES3001533T3 (en) 2019-12-06 2025-03-05 Bae Systems Plc Light source
WO2022087218A1 (en) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Crystalline form of selinexor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019548A1 (en) * 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Hydrazide containing nuclear transport modulators and uses thereof

Also Published As

Publication number Publication date
CN107072992B (zh) 2020-03-10
JP2020143144A (ja) 2020-09-10
NZ728850A (en) 2024-03-22
US20240208943A1 (en) 2024-06-27
AU2020203246A1 (en) 2020-06-04
ZA201700880B (en) 2020-01-29
AU2024202835B2 (en) 2026-07-09
WO2016025904A1 (en) 2016-02-18
AU2021286266B2 (en) 2024-02-01
EP3180331A1 (en) 2017-06-21
CA2957266A1 (en) 2016-02-18
US11807629B2 (en) 2023-11-07
CN111484483B (zh) 2023-05-26
JP7218323B2 (ja) 2023-02-06
US11078190B2 (en) 2021-08-03
CN107072992A (zh) 2017-08-18
US12371420B2 (en) 2025-07-29
AU2021286266A1 (en) 2022-01-06
US20220135545A1 (en) 2022-05-05
US20230242516A1 (en) 2023-08-03
KR20170043561A (ko) 2017-04-21
JP7558310B2 (ja) 2024-09-30
MA40254A (fr) 2021-05-19
JP6777626B2 (ja) 2020-10-28
US20260152489A1 (en) 2026-06-04
EP3180331B1 (en) 2022-06-08
JP2017527549A (ja) 2017-09-21
KR102608259B1 (ko) 2023-11-29
US20200283419A1 (en) 2020-09-10
SG11201700789SA (en) 2017-02-27
AU2015301484A1 (en) 2017-03-02
MX2021014128A (es) 2022-01-04
CN111481553B (zh) 2023-09-01
SG10201808624VA (en) 2018-11-29
EA201790384A1 (ru) 2017-08-31
US10519139B2 (en) 2019-12-31
IL250328A0 (en) 2017-03-30
MA40254B1 (fr) 2022-09-30
DK3180331T3 (da) 2022-09-12
EP4112615A1 (en) 2023-01-04
CN111484483A (zh) 2020-08-04
MX388170B (es) 2025-03-19
IL250328B (en) 2022-05-01
UA123535C2 (uk) 2021-04-21
US11753401B2 (en) 2023-09-12
US20230242517A1 (en) 2023-08-03
CN111481553A (zh) 2020-08-04
ES2926377T3 (es) 2022-10-25
US20180215733A1 (en) 2018-08-02
US11746102B2 (en) 2023-09-05
JP2023052622A (ja) 2023-04-11
AU2020203246B2 (en) 2021-09-16
AU2024202835A1 (en) 2024-05-23
CO2017001884A2 (es) 2017-07-19
MX2017002013A (es) 2017-05-12

Similar Documents

Publication Publication Date Title
US12371420B2 (en) Polymorphs of Selinexor
US10526295B2 (en) Nuclear transport modulators and uses thereof
US10363247B2 (en) (S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
WO2022087218A1 (en) Crystalline form of selinexor
HK40086113A (en) Compositions comprising one crystalline form of selinexor
WO2024102477A1 (en) Crystalline forms of eltanexor and process for preparing same
HK1238240A1 (en) Polymorphs of selinexor
HK1238240B (en) Polymorphs of selinexor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)